IL17A and psoriasis: B-containing microemulsion formulation could be a good candidate for topical anti-psoriasis treatment by reducing the inflammatory response by downregulating the IL-23/IL-17 axis, inhibiting the abnormal proliferation of keratinocytes, and providing sufficient hydration for dry skin.